Metabolism-dependent inhibition of CYP3A4 by lapatinib: Evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1012-1022

  Barbara, Joanna E ^a   Kazmi, Faraz ^a   Parkinson, Andrew ^b   Buckley, David B ^a  

^a XenoTech LLC   (United States)

^b XPD Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC AMINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HEME; HYDROXYLAMINE; IRON; LAPATINIB; NITRONE DERIVATIVE; NITROSO DERIVATIVE; OXIME DERIVATIVE; POTASSIUM FERRICYANIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DEALKYLATION; DEHYDROGENATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MASS SPECTROMETRY; OXIDATION; OXYGENATION; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; NITROGEN OXIDES; OXIMES; QUINAZOLINES;

EID: 84876751119     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.051151     Document Type: Article

References (38)

1. Barbara JE, Kazmi F, Muranjan S, Toren PC, and Parkinson A (2012) High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling. Drug Metab Dispos 40:1966-1975.
2. Beckett AH (1971) Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms. Xenobiotica 1:365-383.
3. Buening MK and Franklin MR (1976) The formation of cytochrome P-450-metabolic intermediate complexes in microsomal fractions from extrahepatic tissues of the rabbit. Drug Metab Dispos 4:556-561.
4. Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, and MacLauchlin C (2012) Human metabolism of lapatinib, a dual kinase inhibitor: Implications for hepatotoxicity. Drug Metab Dispos 40:139-150.
5. Chan EC, New LS, Chua TB, Yap CW, Ho HK, and Nelson SD (2012) Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos 40:1414-1422.
6. Danan G, Descatoire V, and Pessayre D (1981) Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 218:509-514.
7. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr Drug Metab 6:413-454.
8. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, and Arbushites MC, et al. (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005.
9. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, and Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: A perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
10. Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, and Kunze KL (2010) Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: Opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 38:963-972.
11. Jeffery EH and Mannering GJ (1983) Interaction of constitutive and phenobarbital-induced cytochrome P-450 isozymes during the sequential oxidation of benzphetamine. Explanation for the difference in benzphetamine-induced hydrogen peroxide production and 455-nm complex formation in microsomes from untreated and phenobarbital-treated rats. Mol Pharmacol 23: 748-757.
12. Jonsson J and Lindeke B (1976) On the formation of cytochrome P-450 product complexes during the metabolism of phenylalkylamines. Acta Pharm Suec 13:313-320.
13. Jönsson KH and Lindeke B (1992) Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver. Chirality 4:469-477.
14. Lindeke B (1982) The non-and postenzymatic chemistry of N-oxygenated molecules. Drug Metab Rev 13:71-121.
15. Lindeke B, Paulsen U, and Anderson E (1979) Cytochrome P-455 complex formation in the metabolism of phenylalkylamines-IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine. Biochem Pharmacol 28:3629-3635.
16. Lindeke B, Paulsen-Sörman U, Hallström G, Khuthier AH, Cho AK, and Kammerer RC (1982) Cytochrome P-455-nm complex formation in the metabolism of phenylalkylamines. VI. Structure-activity relationships in metabolic intermediary complex formation with a series of alpha-substituted 2-phenylethylamines and corresponding N-hydroxylamines. Drug Metab Dispos 10:700-705.
17. Mansuy D (1981) Use of model systems in biochemical toxicology: Heme models. Biochem Toxicol 3:283-320.
18. Mansuy D, Battioni P, Chottard JC, and Lange M (1977a) Nitrosoalkanes as new ligands of iron (II) porphyrins and hemoproteins. J Am Chem Soc 99:6441-6443.
19. Mansuy D, Beaune P, Chottard JC, Bartoli JF, and Gans P (1976) The nature of the "455 nm absorbing complex" formed during the cytochrome P450 dependent oxidative metabolism of amphetamine. Biochem Pharmacol 25:609-612.
20. Mansuy D, Beaune P, Cresteil T, Bacot C, Chottard JC, and Gans P (1978) Formation of complexes between microsomal cytochrome P-450-Fe(II) and nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes in situ. Eur J Biochem 86: 573-579.
21. Mansuy D, Chottard JC, and Chottard G (1977b) Nitrosoalkanes as Fe(II) ligands in the hemoglobin and myoglobin complexes formed from nitroalkanes in reducing conditions. Eur J Biochem 76:617-623.
22. McNeil CM and Murray M (1996) Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochem Pharmacol 51:15-20.
23. Murray M and Murray K (2003) Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 33:973-987.
24. Nettleton DO and Einolf HJ (2011) Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development. Curr Top Med Chem 11:382-403.
25. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, and Kalgutkar AS (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55: 4896-4933.
26. Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, and Parkinson A (2009) In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 37:2045-2054.
27. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, and Ogilvie BW (2011) An evaluation of the dilution method for identifying metabolismdependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370-1387.
28. Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A, Labropoulou-Karatza C, and Kalofonos H (2011) Lapatinib-induced hepatitis: A case report. World J Gastroenterol 17: 2349-2352.
29. Pessayre D, Descatoire V, Konstantinova-Mitcheva M, Wandscheer JC, Cobert B, Level R, Benhamou PJ, Jaouen M, and Mansuy D (1981) Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450. Biochem Pharmacol 30:553-558.
30. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, and Benhamou JP (1982) Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 31:1699-1704.
31. Polasek TM and Miners JO (2008) Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 65:87-97.
32. Schenkman JB, Wilson BJ, and Cinti DL (1972) Dimethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)-in vivo and in vitro effects of metabolism by rat liver microsomes-formation of an oxygenated complex. Biochem Pharmacol 21:2373-2383.
33. Spraggs CF, Parham LR, Hunt CM, and Dollery CT (2012) Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin Pharmacol Ther 91: 647-652.
34. Takakusa H, Wahlin MD, Zhao C, Hanson KL, New LS, Chan EC, and Nelson SD (2011) Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos 39:1022-1030.
35. Taxak N, Desai PV, Patel B, Mohutsky M, Klimkowski VJ, Gombar V, and Bharatam PV (2012) Metabolic-intermediate complex formation with cytochrome P450: Theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate. J Comput Chem 33:1740-1747.
36. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, and Chan EC (2010) Mechanismbased inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78:693-703.
37. Thyagarajan BS (1958) Oxidations by ferricyanide. Chem Rev 58:439-460.
38. Trieu L and Murray M (2000) Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica 30:131-140.